Cardiovascular Sciences, Inc. (CVSC)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cardiovascular Sciences, Inc. (CVSC) with AI Score 46/100 (Weak). Cardiovascular Sciences, Inc. focuses on developing medical products, including anti-adhesion technology and pyruvate therapy. Market cap: 0, Sector: Consumer cyclical.
Last analyzed: Mar 17, 2026Cardiovascular Sciences, Inc. (CVSC) Consumer Business Overview
Cardiovascular Sciences, Inc. is a technology company focused on developing medical products, including anti-adhesion technology, pyruvate therapy, thromboresistant coatings, human vascular tissue equivalents, and aortic catheters. The company targets unmet needs in cardiac trauma and surgical outcomes, operating within the consumer cyclical sector.
Investment Thesis
Cardiovascular Sciences, Inc. presents a speculative investment opportunity within the medical technology sector, focusing on innovative solutions for cardiac care and surgical outcomes. The company's patented Pyruvate Therapy and Anti Adhesion Technology represent potential value drivers, addressing unmet needs in cardiac trauma and post-surgical recovery. However, the company's market capitalization of $0.00B and negative beta of -93.20 indicate high volatility and potential risks. Growth catalysts include successful clinical trials and regulatory approvals for its key products, particularly Pyruvate Therapy. The development and commercialization of its Thromboresistant Coating and Human Vascular Tissue Equivalent could also drive future growth. Investors should closely monitor the company's progress in securing partnerships, funding, and market adoption of its technologies. The OTC market listing introduces additional risks related to liquidity and disclosure.
Based on FMP financials and quantitative analysis
Key Highlights
- Cardiovascular Sciences, Inc. focuses on developing medical products for cardiac care and surgical outcomes.
- The company's product portfolio includes Anti Adhesion Technology, Pyruvate Therapy, and Thromboresistant Coating.
- Cardiovascular Sciences, Inc. operates in the consumer cyclical sector, specifically within personal products and services.
- The company's market capitalization is $0.00B, indicating a micro-cap status.
- Cardiovascular Sciences, Inc. was formerly known as Beverly Hills Weight Loss and Wellness, Inc.
Competitors & Peers
Strengths
- Proprietary technologies in cardiac care.
- Patented Pyruvate Therapy for cardiac trauma.
- Focus on unmet needs in surgical outcomes.
- Potential for innovation in medical devices.
Weaknesses
- Limited financial resources.
- Dependence on regulatory approvals.
- Small market capitalization.
- OTC market listing.
Catalysts
- Upcoming: Clinical trial results for Pyruvate Therapy.
- Upcoming: Regulatory approval decisions for Anti Adhesion Technology.
- Ongoing: Strategic partnerships with medical device companies.
- Ongoing: Development of Thromboresistant Coating.
- Ongoing: Advancement of Human Vascular Tissue Equivalent.
Risks
- Potential: Clinical trial failures for key products.
- Potential: Regulatory delays or rejections.
- Ongoing: Competition from established medical device companies.
- Ongoing: Limited financial resources.
- Ongoing: OTC market listing and associated risks.
Growth Opportunities
- Expansion of Pyruvate Therapy: Cardiovascular Sciences, Inc. has the opportunity to expand the application of its patented Pyruvate Therapy for treating various cardiac conditions, including ischemic reperfusion injury and heart failure. The market for cardiac therapeutics is substantial, estimated to reach billions of dollars annually. Successful clinical trials and regulatory approvals could drive significant revenue growth for the company. Timeline: Ongoing clinical trials with potential for commercialization within 3-5 years.
- Commercialization of Anti Adhesion Technology: The company's Anti Adhesion Technology products have the potential to address a significant market need in preventing post-surgical scarring. The market for anti-adhesion products is growing, driven by increasing surgical procedures and demand for improved patient outcomes. Successful commercialization of these products could generate substantial revenue for Cardiovascular Sciences, Inc. Timeline: Potential for market entry within 2-3 years following regulatory approvals.
- Development of Thromboresistant Coating: Cardiovascular Sciences, Inc.'s Thromboresistant Coating technology aims to prevent blood clot formation on medical devices, enhancing their safety and efficacy. The market for thromboresistant coatings is expanding, driven by the increasing use of medical devices in cardiovascular procedures. Successful development and commercialization of this technology could provide a competitive advantage. Timeline: Product development and testing ongoing, with potential for commercialization within 3-5 years.
- Advancement of Human Vascular Tissue Equivalent: The company's development of a biocompatible Human Vascular Tissue Equivalent for artery replacement during heart surgeries represents a significant innovation in cardiovascular surgery. The market for vascular grafts and replacements is substantial, driven by the increasing prevalence of cardiovascular diseases. Successful development and clinical validation of this technology could lead to significant market opportunities. Timeline: Long-term development project with potential for clinical trials within 5-7 years.
- Strategic Partnerships and Licensing Agreements: Cardiovascular Sciences, Inc. can pursue strategic partnerships and licensing agreements with larger medical device companies to accelerate the development and commercialization of its technologies. Collaborations with established players in the industry can provide access to funding, expertise, and distribution channels, enhancing the company's growth prospects. Timeline: Ongoing efforts to establish partnerships and licensing agreements.
Opportunities
- Strategic partnerships with medical device companies.
- Expansion of Pyruvate Therapy applications.
- Commercialization of Anti Adhesion Technology.
- Development of new cardiovascular products.
Threats
- Competition from established medical device companies.
- Regulatory hurdles and clinical trial failures.
- Limited access to capital.
- Economic downturn affecting healthcare spending.
Competitive Advantages
- Patented technologies like Pyruvate Therapy.
- Specialized expertise in cardiovascular medical products.
- Potential for first-mover advantage in niche markets.
- Proprietary Anti Adhesion Technology.
About CVSC
Cardiovascular Sciences, Inc., formerly Beverly Hills Weight Loss and Wellness, Inc., was re-established in May 2006 with a focus on developing medical products aimed at improving cardiac care and surgical outcomes. The company's core offerings include Anti Adhesion Technology products designed to prevent post-surgical scarring, addressing a significant concern in surgical procedures. Another key product is Pyruvate Therapy, a patented method intended for treating patients suffering from cardiac trauma, such as ischemic reperfusion injury, heart failure, and bypass surgery. In addition to these therapies, Cardiovascular Sciences is developing a Thromboresistant Coating to prevent blood clot formation on medical devices, enhancing their safety and efficacy. The company is also working on a biocompatible Human Vascular Tissue Equivalent for artery replacement during heart surgeries, offering a potential alternative to traditional methods. Furthermore, Cardiovascular Sciences holds patents for Aortic Catheters, contributing to advancements in cardiovascular procedures. Based in Orlando, Florida, the company aims to innovate and provide solutions in the medical device and cardiac care sectors.
What They Do
- Develop Anti Adhesion Technology products to prevent post-surgical scarring.
- Pioneer Pyruvate Therapy, a patented method for treating cardiac trauma patients.
- Create Thromboresistant Coating to prevent blood clot formation on medical devices.
- Develop a biocompatible Human Vascular Tissue Equivalent for artery replacement.
- Patent Aortic Catheters for cardiovascular procedures.
- Focus on medical product innovation in the cardiovascular space.
Business Model
- Develop and patent medical technologies.
- License or sell patented technologies to medical device companies.
- Generate revenue through product sales upon regulatory approval.
- Pursue strategic partnerships for product development and distribution.
Industry Context
Cardiovascular Sciences, Inc. operates within the medical device and technology sector, which is characterized by constant innovation and regulatory scrutiny. The market for cardiac care and surgical solutions is substantial, driven by an aging population and increasing prevalence of cardiovascular diseases. Companies in this sector face intense competition, requiring them to demonstrate clinical efficacy and secure regulatory approvals to gain market share. Cardiovascular Sciences, Inc. aims to differentiate itself through its patented technologies and focus on unmet needs in cardiac trauma and surgical outcomes.
Key Customers
- Hospitals and surgical centers.
- Cardiologists and cardiovascular surgeons.
- Medical device manufacturers.
- Patients undergoing cardiac procedures.
Financials
Chart & Info
Cardiovascular Sciences, Inc. (CVSC) stock price: Price data unavailable
Latest News
No recent news available for CVSC.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CVSC.
Price Targets
Wall Street price target analysis for CVSC.
MoonshotScore
What does this score mean?
The MoonshotScore rates CVSC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Larry Hooper
CEO
Larry Hooper serves as the Chief Executive Officer of Cardiovascular Sciences, Inc. His background includes experience in the healthcare and medical device industries. Prior to his role at Cardiovascular Sciences, Hooper held various leadership positions in companies focused on medical technology and product development. His expertise spans strategic planning, product commercialization, and business development within the healthcare sector. Hooper's leadership is focused on advancing Cardiovascular Sciences' innovative technologies and expanding its market presence.
Track Record: Under Larry Hooper's leadership, Cardiovascular Sciences, Inc. has focused on developing and patenting medical technologies for cardiac care. Key milestones include the advancement of Pyruvate Therapy and Anti Adhesion Technology. Hooper has overseen efforts to secure partnerships and funding for the company's research and development initiatives. His strategic decisions have aimed to position Cardiovascular Sciences as an innovator in the medical device industry.
CVSC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cardiovascular Sciences, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, and trading activity can be sporadic. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. Investors should exercise extreme caution and conduct thorough due diligence before considering an investment in CVSC.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Lack of regulatory oversight.
- Higher risk of fraud or scams.
- Verify the company's legal registration and standing.
- Review available financial statements and disclosures.
- Assess the company's management team and their experience.
- Research the company's products and market potential.
- Evaluate the company's competitive landscape.
- Understand the risks associated with OTC investing.
- Consult with a financial advisor.
- Patented technologies in cardiac care.
- Focus on medical product innovation.
- Experienced CEO with healthcare background.
- Company history and operational existence.
- Scientific rationale for therapeutic approaches.
What Investors Ask About Cardiovascular Sciences, Inc. (CVSC)
What does Cardiovascular Sciences, Inc. do?
Cardiovascular Sciences, Inc. is a technology company focused on developing medical products for cardiac care and surgical outcomes. The company's core offerings include Anti Adhesion Technology products designed to prevent post-surgical scarring, Pyruvate Therapy for treating cardiac trauma, Thromboresistant Coating to prevent blood clot formation, a Human Vascular Tissue Equivalent for artery replacement, and patented Aortic Catheters. The company aims to innovate and provide solutions in the medical device and cardiac care sectors.
What do analysts say about CVSC stock?
As of 2026-03-17, formal analyst ratings for Cardiovascular Sciences, Inc. (CVSC) are unavailable, likely due to its OTC listing and small market capitalization. Given the lack of analyst coverage, investors should conduct their own thorough due diligence, focusing on the company's technology, clinical trial progress, regulatory pathway, and financial resources. The speculative nature of the stock requires careful assessment of both potential upside and significant risks.
What are the main risks for CVSC?
The main risks for Cardiovascular Sciences, Inc. include clinical trial failures, regulatory hurdles, competition from established medical device companies, limited financial resources, and the risks associated with its OTC market listing. Clinical trial failures could significantly impact the company's product pipeline and future prospects. Regulatory delays or rejections could hinder the commercialization of its technologies. Competition from larger companies with greater resources poses a significant challenge. The OTC listing introduces risks related to liquidity, disclosure, and potential price manipulation.
What are the key factors to evaluate for CVSC?
Cardiovascular Sciences, Inc. (CVSC) currently holds an AI score of 46/100, indicating low score. Key strength: Proprietary technologies in cardiac care.. Primary risk to monitor: Potential: Clinical trial failures for key products.. This is not financial advice.
How frequently does CVSC data refresh on this page?
CVSC prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CVSC's recent stock price performance?
Recent price movement in Cardiovascular Sciences, Inc. (CVSC) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary technologies in cardiac care.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CVSC overvalued or undervalued right now?
Determining whether Cardiovascular Sciences, Inc. (CVSC) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CVSC?
Before investing in Cardiovascular Sciences, Inc. (CVSC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company information and may be limited due to the company's OTC listing.
- AI analysis is pending for CVSC.